San Diego-centered Viking Therapeutics marked itself as a significant competitor during the weight loss drug market place in February following revealing promising info from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection and in March the company un